サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1562329

欧州のヒトワクチンアジュバント：2030年までの市場予測 - 地域分析 - タイプ、用途、エンドユーザー別

Europe Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日
ページ情報
英文 113 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
欧州のヒトワクチンアジュバント：2030年までの市場予測 - 地域分析 - タイプ、用途、エンドユーザー別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 113 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州のヒトワクチンアジュバント市場は、2022年に4億7,233万米ドルと評価され、2030年には13億3,800万米ドルに達すると予測され、2022年から2030年までのCAGRは13.9%と推定されます。

個別化ワクチンの動向が欧州のヒトワクチンアジュバント市場を牽引

欧州のヒトワクチンアジュバント市場では、精密ワクチンや個別化ワクチンの動向が高まっています。これらのワクチンは、患者の疾患の特定の遺伝的または分子的特徴を標的とし、各患者固有の免疫反応に合わせたワクチンの製造を支援します。この技術は、ワクチン接種の有効性と安全性を向上させる可能性があり、がん、感染症、自己免疫疾患などの病気を治療するための個別化ワクチンへの関心の高まりにつながっています。

個別化ワクチンの製造には、こうしたオーダーメイドのワクチンに対する免疫反応を高めるアジュバントが必要です。アジュバントは、免疫系を刺激してワクチンの特異的抗原に対する標的化された強力な反応を発現させるために不可欠です。その結果、個別化ワクチンに対する免疫応答を効果的に高めることができるアジュバントに対する需要が高まっています。近年、個別化ワクチンに対する免疫応答を効果的に高めることができるアジュバントを同定・創出するための研究開発への取り組みが重視されています。例えば、2022年12月、ModernaとMerckは、KEYTRUDA（R）（ペムブロリズマブ）との併用による治験中の個別化mRNAがんワクチンであるmRNA-4157/V940を発表しました。mRNA-4157/V940とKEYTRUDAの併用によるアジュバント治療は、KEYTRUDA単独と比較して、再発または死亡のリスクを44%減少させました。規制機関やヘルスケア組織は、個別化ワクチンが公衆衛生の成果を高める可能性があることを認識しています。例えば、2023年1月、BioNTech社と英国政府は、2030年までに最大10,000人の患者に個別化mRNAがん免疫療法を提供するという広範な了解覚書（MoU）に調印しました。これにより、この分野の研究開発イニシアティブへの資金援助が増加し、個別化ワクチンとアジュバントの規制ルートを迅速化する措置がとられました。そのため、個別化ワクチン接種に対する免疫反応を効果的に改善するアジュバントがますます開発され、ワクチンの有効性と安全性を高めています。この動向は、欧州のヒトワクチンアジュバント市場における大幅な技術革新と投資の原動力となっています。

欧州のヒトワクチンアジュバント市場概要

ドイツは、欧州および世界有数の医薬品市場です。ドイツ貿易投資総省（GTAI）によると、欧州連合（EU）最大の医薬品製造拠点であり、約600の製薬会社が存在します。GTAIによると、ドイツの医薬品生産量は2022年に618億米国ドル（約565億円）に達します。さらに、同国は米国に次いでバイオ医薬品の生産で第2位にランクされており、その理由として、良好な産業インフラ、持続的に成長する地元化学産業、高度に有能な労働力の確保が挙げられます。同じ情報源によると、ドイツの製薬業界は2021年に研究開発に約95億米ドル（約88億円）を投資しており、これは他のどの業界の研究開発投資額よりも高いです。欧州最大の人口を擁するドイツのヘルスケア部門は、大きな成長機会を持つ非常に魅力的な市場です。平均寿命の着実な伸びにより、慢性疾患や加齢性疾患が増加しています。感染症の増加は予防接種の需要に拍車をかけると予想されます。例えば、ICO/IARC Information Centre on HPV and Cancer in 2023の報告書によると、ドイツにはHPV関連の子宮頸がんを発症するリスクのある15歳以上の女性が3,660万人います。さらに、ドイツは肝炎の有病率が高いです。感染症の流行による健康意識の向上は、医薬品、ワクチン、治療薬に対する消費者の需要をさらに高めています。このように、ヒトワクチンアジュバントの需要は、感染症の蔓延の増加とともに、製薬会社における医薬品研究開発の盛んな状況とともに、ドイツで急速に拡大しています。

欧州のヒトワクチンアジュバント市場の収益と2030年までの予測（金額）

欧州のヒトワクチンアジュバント市場セグメンテーション

欧州のヒトワクチンアジュバント市場は、タイプ、用途、エンドユーザー、国に分類されます。

タイプ別では、欧州のヒトワクチンアジュバント市場は、微粒子アジュバント、乳剤アジュバント、配合アジュバント、その他に区分されます。2022年には粒子状アジュバントセグメントが最大の市場シェアを占めました。

用途別では、欧州のヒトワクチンアジュバント市場は、インフルエンザ、肝炎、ヒト乳頭腫ウイルス（HPV）、その他に分類されます。2022年にはインフルエンザ分野が最大の市場シェアを占めました。

エンドユーザー別では、欧州のヒトワクチンアジュバント市場は製薬・バイオテクノロジー企業、CMO・CRO、その他に分類されます。2022年には製薬・バイオテクノロジー企業が最大の市場シェアを占めました。

国別では、欧州のヒトワクチンアジュバント市場はドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。2022年の欧州のヒトワクチンアジュバント市場シェアはドイツが独占。

Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA、SPI Pharma Incは欧州のヒトワクチンアジュバント市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州のヒトワクチンアジュバント市場：主要市場力学

  • 欧州のヒトワクチンアジュバント市場：主要市場力学
  • 市場促進要因
    • 慢性疾患の増加
    • 予防接種プログラムへの注目の高まり
  • 市場抑制要因
    • 製造の複雑さと規制上の課題
  • 市場機会
    • 製薬業界の成長
  • 今後の動向
    • 個別化ワクチンの動向の高まり
  • 促進要因と抑制要因の影響

第5章 ヒトワクチンアジュバント市場：欧州市場分析

  • ヒトワクチンアジュバントの欧州市場収益、2020年～2030年
  • ヒトワクチンアジュバントの欧州市場予測分析

第6章 欧州のヒトワクチンアジュバント市場分析：タイプ別

  • 粒子状アジュバント
  • エマルジョンアジュバント
  • 配合アジュバント
  • その他

第7章 欧州のヒトワクチンアジュバント市場分析：用途別

  • インフルエンザ
  • 肝炎
  • ヒト乳頭腫ウイルス（HPV）
  • その他

第8章 欧州のヒトワクチンアジュバント市場分析：エンドユーザー別

  • 製薬企業およびバイオテクノロジー企業
  • CMOおよびCRO
  • その他

第9章 欧州のヒトワクチンアジュバント市場：国別分析

  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州

第10章 業界情勢

第11章 企業プロファイル

  • Novartis AG
  • Dynavax Technologies Corp
  • CSL Ltd
  • Seppic SA
  • SPI Pharma Inc
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
  • Creative Biolabs Inc

第12章 付録

図表

List Of Tables

  • Table 1. Europe Human Vaccine Adjuvants Market Segmentation
  • Table 2. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 4. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 5. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
  • Table 6. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 8. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 9. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 10. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 11. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 12. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 13. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 14. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 15. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 16. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 17. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 18. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 19. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 20. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 21. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 23. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
  • Table 25. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

  • Figure 1. Europe Human Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
  • Figure 4. Europe Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 5. Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
  • Figure 10. Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Human papilloma virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Europe Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
  • Figure 15. Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
  • Figure 19. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 20. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 21. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 22. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 23. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 24. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
目次
Product Code: BMIRE00030406

The Europe human vaccine adjuvants market was valued at US$ 472.33 million in 2022 and is expected to reach US$ 1,338.00 million by 2030; it is estimated to register a CAGR of 13.9% from 2022 to 2030.

Rising Trend of Personalized Vaccines Drives Europe Human Vaccine Adjuvants Market

Precision or personalized vaccines are a growing trend in the Europe human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.

Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Europe human vaccine adjuvants market.

Europe Human Vaccine Adjuvants Market Overview

Germany is one of the top pharmaceutical markets in Europe and worldwide. According to Germany Trade & Invest (GTAI), it is the biggest pharmaceutical manufacturing location in the European Union, with approximately 600 pharmaceutical companies. According to GTAI, pharmaceutical production volume in Germany reached ~US$ 61.8 billion (~ 56.5 billion) in 2022. Further, the country ranks second in biopharmaceutical production after the US, which is attributed to favorable industrial infrastructure, a sustainably growing local chemicals industry, and highly qualified workforce availability. According to the same source, the pharmaceutical industry in Germany invested almost US$ 9.5 billion (~ 8.8 billion) in R&D in 2021, which is higher than the amounts invested in the R&D of any other industry. Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive market with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in chronic and age-related illnesses. An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. For instance, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Germany has a population of 36.6 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Additionally, Germany has a high prevalence of hepatitis. Improved health awareness due to the prevalence of infectious diseases has further increased consumer demand for drugs, vaccines, and therapies. Thus, the demand for human vaccine adjuvants is growing rapidly in Germany with the flourishing pharmaceutical R&D landscape in pharmaceutical companies, alongside the increasing prevalence of infectious diseases.

Europe Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Human Vaccine Adjuvants Market Segmentation

The Europe human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe human vaccine adjuvants market share in 2022.

Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Europe human vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Human Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 Europe Human Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic Diseases
    • 4.2.2 Growing Focus on Immunization Programs
  • 4.3 Market Restraints
    • 4.3.1 Manufacturing Complexities and Regulatory Challenges
  • 4.4 Market Opportunities
    • 4.4.1 Growing Pharmaceutical Industry
  • 4.5 Future Trends
    • 4.5.1 Rising Trend of Personalized Vaccines
  • 4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Europe Market Analysis

  • 5.1 Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
  • 5.2 Europe Human Vaccine Adjuvants Market Forecast Analysis

6. Europe Human Vaccine Adjuvants Market Analysis - by Type

  • 6.1 Particulate Adjuvant
    • 6.1.1 Overview
    • 6.1.2 Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.2 Emulsion Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Combination Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Others
    • 6.4.1 Overview
    • 6.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Human Vaccine Adjuvants Market Analysis - by Application

  • 7.1 Influenza
    • 7.1.1 Overview
    • 7.1.2 Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Hepatitis
    • 7.2.1 Overview
    • 7.2.2 Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Human Papilloma Virus (HPV)
    • 7.3.1 Overview
    • 7.3.2 Human Papilloma Virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Human Vaccine Adjuvants Market Analysis - by End User

  • 8.1 Pharmaceutical and Biotechnology Companies
    • 8.1.1 Overview
    • 8.1.2 Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 CMOs and CROs
    • 8.2.1 Overview
    • 8.2.2 CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Human Vaccine Adjuvants Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
      • 9.1.1.1 Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.1.1 Germany Vaccine Adjuvants Market Breakdown, by Type
        • 9.1.1.1.2 Germany Vaccine Adjuvants Market Breakdown, by Application
        • 9.1.1.1.3 Germany Vaccine Adjuvants Market Breakdown, by End User
      • 9.1.1.2 UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.2.1 UK Human Vaccine Adjuvants Market Breakdown, by Type
        • 9.1.1.2.2 UK Human Vaccine Adjuvants Market Breakdown, by Application
        • 9.1.1.2.3 UK Human Vaccine Adjuvants Market Breakdown, by End User
      • 9.1.1.3 France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.3.1 France Human Vaccine Adjuvants Market Breakdown, by Type
        • 9.1.1.3.2 France Human Vaccine Adjuvants Market Breakdown, by Application
        • 9.1.1.3.3 France Human Vaccine Adjuvants Market Breakdown, by End User
      • 9.1.1.4 Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.4.1 Italy Human Vaccine Adjuvants Market Breakdown, by Type
        • 9.1.1.4.2 Italy Human Vaccine Adjuvants Market Breakdown, by Application
        • 9.1.1.4.3 Italy Human Vaccine Adjuvants Market Breakdown, by End User
      • 9.1.1.5 Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.5.1 Spain Vaccine Adjuvants Market Breakdown, by Type
        • 9.1.1.5.2 Spain Vaccine Adjuvants Market Breakdown, by Application
        • 9.1.1.5.3 Spain Vaccine Adjuvants Market Breakdown, by End User
      • 9.1.1.6 Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.6.1 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Type
        • 9.1.1.6.2 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Application
        • 9.1.1.6.3 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

  • 10.1 Overview

11. Company Profiles

  • 11.1 Novartis AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Dynavax Technologies Corp
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 CSL Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Seppic SA
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 SPI Pharma Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Croda International Plc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Novavax Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Phibro Animal Health Corp
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Creative Biolabs Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms